Home > Healthcare > Pharmaceuticals > Finished Drug Form > Triptorelin Market

Triptorelin Market Size

Report ID: GMI5427
Published Date: Feb 2023
Report Format: PDF

Download Free Sample

Triptorelin Market Size

Triptorelin Market size was valued at over USD 910 million in 2022. Driven by the growing occurrence of endometriosis across the global female population, industry is expected to grow at over 5% CAGR from 2023 to 2032.

To get key market trends

Download Free Sample

Endometriosis is a disease that leads to scar tissue formation within the pelvis due to a chronic inflammatory response caused by the presence of endometrium outside the uterus. As per estimates, around 176 million women across the globe, around one in ten, suffer from endometriosis in their reproductive years, typically between the ages of 15 and 49. Triptorelin is efficacious in alleviating the pain symptoms caused by endometriosis. It has a favorable safety profile and has also been shown to improve reproductive function. Subsequently, it is commonly used to treat deep infiltrating endometriosis (DIE) among women.

Triptorelin Market Report Attributes
Report Attribute	Details
Base Year:	2022
Triptorelin Market Size in 2022:	USD 913 Million
Forecast Period:	2023 to 2032
Forecast Period 2023 to 2032 CAGR:	5%
2032 Value Projection:	USD 1.49 Billion
Historical Data for:	2018 to 2022
No. of Pages:	320
Tables, Charts & Figures:	373
Segments covered:	Drug, Product form, Application, Route of Administration, Distribution Channel, and Region
Growth Drivers:	Rising incidence of cancer worldwide Increasing drug-related research and development activities Growing number of women population base suffering from endometriosis Upsurge in awareness regarding precocious puberty
Pitfalls & Challenges:	High cost associated with triptorelin drugs Adverse drug price control policies

Learn more about the key segments shaping this market

Download Free Sample

Steep prices of triptorelin drugs may hamper industry outlook

Despite an extensive customer pool, triptorelin market faces a major challenge in the form of the high manufacturing cost of triptorelin drugs, which translates into steep medication prices for customers. Given that the raw materials utilized are specific to the drug, the quality of raw materials used in drug development is crucial, which further elevates costs. Meanwhile, the complexity of triptorelin manufacturing process, which entails a wide range of biological or chemical processes, is also impeding product adoption by limiting product availability to those who can afford it.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global market size for triptorelin held a valuation of over USD 910 million in 2022 and is projected to grow at over 5% CAGR from 2023 to 2032, on account of surging occurrence of endometriosis across the global female population.

The triptorelin market size from the intradermal segment is anticipated to grow at over 4.5% CAGR from 2023 to 2032, fueled by the growing number of hormone therapies performed annually across the globe.

Europe triptorelin business valuation is poised to surpass USD 370 million by 2032, owing to the growing prevalence of diseases such as cancer and endometriosis in the region, coupled with increasing government investments towards the health and well-being of its citizens.

Some of the major triptorelin industry contenders include Taj Pharmaceuticals Limited., Anhui Anke Bioengineering (Group) Co., Ltd., Biozenta Lifescience Pvt. Ltd, Azurity Pharmaceuticals, Inc., and Verity Pharmaceuticals Inc., among others.